Rheumatology

Genetics, Variants, and How TRAPS is Diagnosed

At a Glance

TRAPS is diagnosed by combining symptoms, flare patterns, and TNFRSF1A genetic results—not by a genetic test alone. High-penetrance variants, low-penetrance changes, and somatic mosaicism can affect how results are interpreted and whether further testing is needed.

The diagnosis of Tumor Necrosis Factor Receptor 1 Associated Periodic Syndrome (TRAPS) is a puzzle that combines your clinical history, physical symptoms, and genetic information. Because TRAPS symptoms can overlap with other fever syndromes, doctors use clinical judgment alongside frameworks like the Eurofever/PRINTO classification criteria to help categorize the disease ^[1].

It is important to understand that classification criteria are designed primarily to group patients consistently for research, not as an absolute diagnostic checklist. A specialist’s diagnosis involves excluding look-alike conditions and carefully interpreting your specific genetic variant.

The Genetic Blueprint: TNFRSF1A

TRAPS is caused by mutations in the TNFRSF1A gene. You inherit this condition in an autosomal dominant manner, meaning you only need one copy of the mutated gene to potentially develop the disease ^[2]. However, genetics in TRAPS are complex, and mutations are categorized based on how strongly they cause disease:

Structural Variants and Cysteine Substitutions: These mutations—especially those that affect a specific amino acid called cysteine—alter the structure of the receptor and often cause more severe, classic TRAPS ^[3]. These high-penetrance variants tend to cause longer flares, higher levels of baseline inflammation, and carry a higher risk of AA amyloidosis (a serious kidney complication) ^[4]^[5]. Historical cohorts observed amyloidosis in 16% to 25% of untreated patients with these variants, though modern treatments actively reduce this risk.
Low-Penetrance Variants (e.g., R92Q): These are genetic changes that may cause milder symptoms or shorter flares ^[6]. A low-penetrance variant can sometimes be found in the general population in people without classic TRAPS ^[7]^[3]. Having this variant does not establish a diagnosis of TRAPS on its own; your symptoms must match.
Variant of Uncertain Significance (VUS): This means a genetic change was found, but researchers do not yet have enough evidence to know if it actually causes disease. A VUS alone does not confirm TRAPS ^[1]^[8].

Differentiating TRAPS from “Look-Alikes”

Because a genetic test alone doesn’t always provide a definitive answer, your doctor will check for “look-alike” conditions by comparing the length and nature of your flares:

TRAPS: Typically features flares lasting longer than 7 days, often with eye swelling (periorbital edema) and migrating muscle pain ^[6]^[9].
FMF (Familial Mediterranean Fever): Usually causes very short flares (1–3 days) and is more commonly associated with intense joint or abdominal pain ^[10]^[11].
MKD (Mevalonate Kinase Deficiency): Often includes swollen lymph nodes and mouth sores (aphthous ulcers) ^[12].
CAPS (Cryopyrin-Associated Periodic Syndromes): Frequently features a hives-like rash and can be triggered by exposure to cold ^[13].

Somatic Mosaicism: The “Hidden” Mutation

In most cases of TRAPS, the genetic mutation is present in every cell of the body (a germline mutation). However, some patients—particularly those who develop symptoms for the first time as adults—may have somatic mosaicism ^[14].

This means the mutation happened after conception and is only present in some of the body’s cells. Because these mutations are “hidden” in only a fraction of the blood cells, they may be missed by standard genetic tests ^[15]. If you have classic TRAPS symptoms but your initial genetic test was negative, your specialist might order “high-depth” sequencing (a more sensitive test) to look for these mosaic variants ^[14]^[16].

Common questions in this guide

What gene causes TRAPS, and how is the condition inherited?

TRAPS is caused by changes in the TNFRSF1A gene. It usually follows an autosomal dominant pattern, meaning one altered copy can be enough for a person to develop the condition.

Can a TNFRSF1A result by itself diagnose TRAPS?

No. A high-penetrance disease-causing variant can support the diagnosis, but a low-penetrance change such as R92Q or a variant of uncertain significance does not confirm TRAPS on its own. Clinicians interpret the result alongside symptoms and exclude similar fever syndromes.

What symptoms make TRAPS different from other periodic fever syndromes?

TRAPS commonly causes flares lasting longer than seven days, swelling around the eyes, and muscle pain that moves from one area to another. Familial Mediterranean fever more often causes one- to three-day flares with strong joint or abdominal pain, while MKD and CAPS have characteristic mouth sores, swollen lymph nodes, or a hives-like rash and cold triggers.

What does a variant of uncertain significance mean in TRAPS testing?

It means the genetic test found a TNFRSF1A change, but there is not enough evidence to know whether it causes disease. A VUS should not be treated as proof of TRAPS; your specialist will weigh your symptoms, family history, and other test results.

Could somatic mosaicism explain TRAPS symptoms when genetic testing is negative?

Possibly. Somatic mosaicism means the TNFRSF1A change is present in only some cells, so a standard blood test may miss it. If symptoms strongly resemble TRAPS, a specialist may consider high-depth sequencing, which can detect lower levels of the variant.

What does an R92Q or other low-penetrance variant mean?

A low-penetrance variant may be associated with milder symptoms or shorter flares, and it can also occur in people without classic TRAPS. Finding R92Q alone does not establish the diagnosis; the result must match the person's clinical symptoms.

Do certain TRAPS variants increase the risk of kidney complications?

Yes. High-penetrance variants that alter receptor structure, especially cysteine substitutions, have been linked with a higher risk of AA amyloidosis, a serious kidney complication. Modern treatment can reduce this risk, but your specialist should interpret it in light of your variant and inflammation history.

Curated prompts to bring to your next appointment.

1.What specific TNFRSF1A variant was found in my genetic report, and how is it currently classified (e.g., pathogenic, low-penetrance, or a VUS)?
2.Does my variant involve a structural change or a cysteine substitution, and how does that affect my long-term risk for kidney complications?
3.How do my symptoms align with the Eurofever/PRINTO classification criteria for TRAPS?
4.If my genetic testing is inconclusive but my symptoms are strong, could somatic mosaicism explain my condition, and would further high-depth testing be helpful?
5.How does the duration and nature of my flares help you distinguish my case from look-alike conditions like FMF or MKD?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

TRAPS diagnosis combines clinical history, symptom patterns, genetic findings, and evaluation for similar periodic fever syndromes; classification criteria are not an absolute diagnostic checklist.
TRAPS is caused by TNFRSF1A variants and usually follows an autosomal dominant inheritance pattern, so one altered copy may be enough to cause disease.
High-penetrance structural or cysteine-substitution variants are often associated with longer flares and a greater risk of AA amyloidosis than low-penetrance variants such as R92Q.
A variant of uncertain significance or a low-penetrance variant alone does not confirm TRAPS; the genetic result must fit the person's symptoms.
High-depth sequencing may help identify somatic mosaicism when classic TRAPS symptoms persist despite a negative standard genetic test.

References (16)

1
Classification criteria for autoinflammatory recurrent fevers.
Gattorno M, Hofer M, Federici S, et al.
Annals of the rheumatic diseases 2019; (78(8)):1025-1032 doi:10.1136/annrheumdis-2019-215048.
PMID: 31018962
2
Tumor necrosis factor receptor-associated cycle syndrome: a case report and literature review.
Li Z, Jing X, Zhang S, et al.
Frontiers in pediatrics 2023; (11()):1296487 doi:10.3389/fped.2023.1296487.
PMID: 38155741
3
Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center.
Nezos A, Argyropoulou OD, Klinaki E, et al.
Rheumatology (Oxford, England) 2020; (59(6)):1241-1246 doi:10.1093/rheumatology/kez424.
PMID: 31562507
4
Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network.
Gaggiano C, Vitale A, Obici L, et al.
Mediators of inflammation 2020; (2020()):8562485 doi:10.1155/2020/8562485.
PMID: 32831641
5
INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry.
Papa R, Lane T, Minden K, et al.
The journal of allergy and clinical immunology. In practice 2021; (9(2)):783-791.e4 doi:10.1016/j.jaip.2020.10.053.
PMID: 33181346
6
Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant.
Camprubí D, Mitjavila F, Arostegui JI, Corbella X
International journal of rheumatic diseases 2017; (20(4)):510-514 doi:10.1111/1756-185X.13029.
PMID: 27990755
7
Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene.
Ruiz-Ortiz E, Iglesias E, Soriano A, et al.
Frontiers in immunology 2017; (8()):299 doi:10.3389/fimmu.2017.00299.
PMID: 28396659
8
Validation of the new classification criteria for hereditary recurrent fever in an independent cohort: experience from the JIR Cohort Database.
Dingulu G, Georgin-Lavialle S, Koné-Paut I, et al.
Rheumatology (Oxford, England) 2020; (59(10)):2947-2952 doi:10.1093/rheumatology/keaa031.
PMID: 32125423
9
Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature.
Chen Y, Huang X, Zheng S, et al.
Clinical rheumatology 2018; (37(5)):1433-1438 doi:10.1007/s10067-018-4023-4.
PMID: 29450850
10
[Periodic fever syndrome associated with mutations in the TNF type 1 receptor gene: A differential diagnosis of familial Mediterranean fever that should not be overlooked in patients of Mediterranean origin].
Bourguiba R, Savey L, Aouba A, et al.
La Revue de medecine interne 2021; (42(7)):459-464 doi:10.1016/j.revmed.2020.08.007.
PMID: 33131906
11
FMF is not always "fever": from clinical presentation to "treat to target".
Maggio MC, Corsello G
Italian journal of pediatrics 2020; (46(1)):7 doi:10.1186/s13052-019-0766-z.
PMID: 31941537
12
Recurrent macrophage activation syndrome due to hyperimmunoglobulin D syndrome: a case-based review.
Gezgin Yıldırım D, Yıldız Yıldırım Ç, Karaçayır N, et al.
Clinical rheumatology 2023; (42(1)):277-283 doi:10.1007/s10067-022-06384-9.
PMID: 36149537
13
The many faces of pediatric urticaria.
Sekerel BE, Ilgun Gurel D, Sahiner UM, et al.
Frontiers in allergy 2023; (4()):1267663 doi:10.3389/falgy.2023.1267663.
PMID: 38026129
14
Somatic mosaicism in adult-onset TNF receptor-associated periodic syndrome (TRAPS).
Kontzias A, Zarabi SK, Calabrese C, et al.
Molecular genetics & genomic medicine 2019; (7(8)):e791 doi:10.1002/mgg3.791.
PMID: 31397119
15
Redefining the Landscape: Acquired Mutations Driving Systemic Autoinflammatory Diseases.
Rowczenio D, Omoyinmi E, Brown J, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2026; doi:10.1002/art.70282.
PMID: 42529936
16
Mosaicism in autoinflammatory diseases: Cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review.
Labrousse M, Kevorkian-Verguet C, Boursier G, et al.
Critical reviews in clinical laboratory sciences 2018; (55(6)):432-442 doi:10.1080/10408363.2018.1488805.
PMID: 30035647

This page is for informational purposes only and does not constitute medical advice. A qualified healthcare professional should interpret your TNFRSF1A results alongside your symptoms and family history.

Get notified when new evidence is published on Tumor necrosis factor receptor 1 associated periodic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents